Heidelberg Pharma AG Akt. nach Kapitalherabsetzung HPHA
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Trading Information
- Previous Close Price
- €3.01
- Day Range
- €2.96–3.00
- 52-Week Range
- €2.63–4.07
- Bid/Ask
- €0.00 / €0.00
- Market Cap
- €138.88 Mil
- Volume/Avg
- 7,119 / 10,359
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 15.33
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
Heidelberg Pharma AG is a biopharmaceutical company. It is focused on oncology and develops the toxin Amanitin into cancer therapies using its proprietary Antibody Targeted Amanitin Conjugate (ATAC) technology platform and advances the biological mode of action of the toxin as a novel therapeutic principle. The proprietary lead candidate is HDP-101 which is a BCMA (B-cell maturation antigen) - ATAC for multiple myeloma. In addition, the company offers preclinical contract research services. It operates through the following business divisions: Customer Specific Research, Diagnostics, and TherapeuticS.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Growth
- Total Number of Employees
- 105
Comparables
Valuation
|
Metric
|
HPHA
|
CLDX
|
ANAB
|
|---|---|---|---|
Price/Earnings (Normalized) | — | — | — |
Price/Book Value | 3.77 | 5.12 | 7.86 |
Price/Sales | 15.33 | 276.98 | 40.83 |
Price/Cash Flow | — | — | — |
Price/Earnings
HPHA
CLDX
ANAB
Financial Strength
|
Metric
|
HPHA
|
CLDX
|
ANAB
|
|---|---|---|---|
Quick Ratio | 2.18 | 13.69 | 10.62 |
Current Ratio | 2.92 | 13.87 | 10.87 |
Interest Coverage | −34.44 | — | −9.09 |
Quick Ratio
HPHA
CLDX
ANAB
Profitability
|
Metric
|
HPHA
|
CLDX
|
ANAB
|
|---|---|---|---|
Return on Assets (Normalized) | −22.72% | −30.49% | −23.50% |
Return on Equity (Normalized) | −38.22% | −33.19% | −75.96% |
Return on Invested Capital (Normalized) | −32.03% | −32.85% | −68.56% |
Return on Assets
HPHA
CLDX
ANAB
Biotechnology Industry Comparables
|
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|
NVO
| Novo Nordisk A/S ADR | Bjydxxjdn | Dxsg | $572.7 Bil | |
VRTX
| Vertex Pharmaceuticals Inc | Fsqgmthn | Dlckry | $103.9 Bil | |
REGN
| Regeneron Pharmaceuticals Inc | Hhbzvnfw | Mdmbld | $99.2 Bil | |
MRNA
| Moderna Inc | Tkqgwfnr | Vrdds | $42.7 Bil | |
ARGX
| argenx SE ADR | Yznjjmgkl | Fgg | $22.2 Bil | |
BNTX
| BioNTech SE ADR | Mqnrxfdw | Plq | $21.7 Bil | |
ALNY
| Alnylam Pharmaceuticals Inc | Tgbjdnlld | Rgbkm | $19.0 Bil | |
BMRN
| Biomarin Pharmaceutical Inc | Mrrccsdbx | Brgtp | $15.8 Bil | |
RPRX
| Royalty Pharma PLC Class A | Flqzchyfkr | Rsdpqs | $12.7 Bil | |
INCY
| Incyte Corp | Wmzswlh | Dtknwc | $11.9 Bil |